Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PULSE BIOSCIENCES, INC.PLSE · Entity 1151 | Director | May 20, 2021 | May 21, 2021 |
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PULSE BIOSCIENCES, INC.
Report date May 20, 2021 · Filed May 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.69 · Expires 2031-05-20 | Direct | 20,000 |
Reported balance
After 2021-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-20 · Grant · Acquired 20,000 · Balance 20,000 F1: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.69 · Expires 2031-05-20 | Direct | 8,026 |
Reported balance
After 2021-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-20 · Grant · Acquired 8,026 · Balance 8,026 F2: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date.
F2: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date.
Summit Therapeutics Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 35,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.52 · Expires 2036-01-02 | Direct | 17,796 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 17,796 · Balance 17,796 F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $155,900. F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $155,900.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 18:43 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 17,796 | $8.76 Strike: $17.52 | $155,892.96 |
DisclosureSEC source: 0001561736-26-000002 · wk-form4_1767742986.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,796 Underlying: Common Stock · 17,796 shares Expires 2036-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $155,900. F3 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 18:43 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $17.52 | Not disclosed |
DisclosureSEC source: 0001561736-26-000002 · wk-form4_1767742986.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2026. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:05 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 16,991 | $9.18 Strike: $18.35 | $155,977.38 |
DisclosureSEC source: 0001599298-25-000023 · wk-form4_1736208323.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,991 Underlying: Common Stock · 16,991 shares Expires 2035-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuers Director Retainer Option Election Plan in lieu of retainer fees of $155,900 F3 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 19:05 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $18.35 | Not disclosed |
DisclosureSEC source: 0001599298-25-000023 · wk-form4_1736208323.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2035-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2025. The shares underlying the option shall vest in four quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the reporting person remaining as a non-salaried director on each such vesting date. Read SEC document |
| October 11, 2024 Filed Oct 15, 2024 17:08 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $19.95 | Not disclosed |
DisclosureSEC source: 0001599298-24-000150 · wk-form4_1729026485.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-10-11 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on October 11, 2024. The shares underlying the option shall vest in four equal annual installments, subject to the reporting person continuing to serve as a member of the Strategic Advisory Committee of the Board, with the first installment occurring on October 11, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:24 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 70,492 | $1.32 Strike: $2.64 | $93,049.44 |
DisclosureSEC source: 0001599298-24-000012 · wk-form4_1704403461.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,492 Underlying: Common Stock · 70,492 shares Expires 2034-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $93,050. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:24 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000012 · wk-form4_1704403461.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 44,400 | $1.67 Strike: $5.00 | $74,148.00 |
DisclosureSEC source: 0001599298-23-000004 · wf-form4_167295314354996.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,400 Underlying: Common Stock · 44,400 shares Expires 2033-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $74,000. F3 · derivative.exercise_date: The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 16:12 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001599298-23-000004 · wf-form4_167295314354996.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:01 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 58,510 | $1.13 Strike: $2.82 | $66,116.30 |
DisclosureSEC source: 0001599298-22-000005 · wf-form4_164141648612518.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,510 Underlying: Common Stock · 58,510 shares Expires 2032-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $66,000. F3 · derivative.exercise_date: The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 16:01 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.82 | Not disclosed |
DisclosureSEC source: 0001599298-22-000005 · wf-form4_164141648612518.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 08:40 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 6,250 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0000921895-21-002408 · form412566003_10112021.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,250 Underlying: Common Stock · 6,250 shares Expires 2031-10-07 F3 · price: Not applicable. F2 · derivative.exercise_date: The option was granted on October 7, 2021 and represents a pro rata amount of the annual 25,000 option board grant based approximately on the number of days this year the reporting person is anticipated to serve as a director. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
| October 07, 2021 Filed Oct 12, 2021 08:40 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 200,000 | Not disclosed Strike: $5.03 | Not disclosed |
DisclosureSEC source: 0000921895-21-002408 · form412566003_10112021.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2031-10-07 F3 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on October 7, 2021. The shares underlying the option are scheduled to vest in four equal annual installments, with the first such installment occurring on October 7, 2022. Read SEC document |
| May 20, 2021 Filed May 21, 2021 17:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 8,026 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035006 · doc4.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,026 Underlying: Common Stock · 8,026 shares Expires 2031-05-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 20, 2021 Filed May 21, 2021 17:05 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $18.69 | $0.00 |
DisclosureSEC source: 0001209191-21-035006 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 18, 2020 Filed May 19, 2020 18:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 14,071 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030672 · doc4.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,071 Underlying: Common Stock · 14,071 shares Expires 2030-05-18 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 18, 2020 Filed May 19, 2020 18:21 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $10.66 | $0.00 |
DisclosureSEC source: 0001209191-20-030672 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 16:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 9,900 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-030882 · doc4.xml · derivative · entry 2 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,900 Underlying: Common Stock · 9,900 shares Expires 2029-05-16 F2 · derivative.exercise_date: The shares subject to the option will vest in equal quarterly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| May 16, 2019 Filed May 17, 2019 16:14 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.03 | $0.00 |
DisclosureSEC source: 0001209191-19-030882 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 16:12 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 2,931 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0001209191-19-003029 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,931 Underlying: Common Stock · 2,931 shares Expires 2029-01-07 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the date of the Issuer's Annual Meeting to be held in 2019, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 23, 2018 Filed May 24, 2018 18:35 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $15.27 | $0.00 |
DisclosureSEC source: 0001209191-18-033146 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over a one year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
| November 02, 2017 Filed Nov 6, 2017 16:42 UTC | PULSE BIOSCIENCES, INC. PLSE · Entity 1151 | GrantStock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $23.08 | $0.00 |
DisclosureSEC source: 0001209191-17-059424 · doc4.xml · derivative · entry 1 Clark Kenneth A · CIK 0001561736 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2027-11-02 F1 · derivative.exercise_date: One-third (1/3) of the shares subject to the option will vest on November 2, 2018, and the remaining shares will vest in equal monthly installments thereafter over the following two year period, subject to the Reporting Person's continued service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.